$IVST Record Sales, Major Clients, Significant Gro
Post# of 18536
(Total Views: 184)
Posted On: 07/23/2018 10:50:34 AM
$IVST Record Sales, Major Clients, Significant Growth Mark 1st Half 2018 Letter to Shareholders, Q2 Report
Congratulations and thank you to our team, investors, and shareholders: Our stock price is up 725% on the year, on closing and integrating five acquisitions and managing them to three consecutive record sales months. These facts validate our business model and as a result, we are focused on significant growth opportunities. Other notable highlights:
Sales are up 55.8%. ($1,104,367 in Q2 compared to $708,804 in Q1). June Sales were highest ever, at 16.8% higher than May, the previous record.
End Q2 current assets of $877,861 include cash on hand of $561,062.
Our capital structure includes an unchanged free-trading float of 11,796,710 common shares. There are no convertible debts, no warrants or options outstanding.
Our headcount is 44 employees, up from 26 at the start of the quarter.
Our stock price is up 725% as of this past Friday, since our January 2, 2018 close. Since Thursday of last week IVST saw more than double average trading volume, following the StemVax announcement.
We received notice that Winslow Asset Management registered as a shareholder, marking our first institutional shareholder position.
We closed several key contracts with organizations ranging from local governments, to the United States Navy, University Hospitals, Cleveland Indians, University of Louisiana, Iowa Department of Transportation, Houston Metro, Tarkette and a $650K exclusive contact from Byram Healthcare, a division of a Fortune 500 Company.
We’ve got a world-class team including two independent members of our Board of Directors, and our key corporate leadership is highlighted on our new corporate website.
https://finance.yahoo.com/news/innovest-globa...00125.html
Congratulations and thank you to our team, investors, and shareholders: Our stock price is up 725% on the year, on closing and integrating five acquisitions and managing them to three consecutive record sales months. These facts validate our business model and as a result, we are focused on significant growth opportunities. Other notable highlights:
Sales are up 55.8%. ($1,104,367 in Q2 compared to $708,804 in Q1). June Sales were highest ever, at 16.8% higher than May, the previous record.
End Q2 current assets of $877,861 include cash on hand of $561,062.
Our capital structure includes an unchanged free-trading float of 11,796,710 common shares. There are no convertible debts, no warrants or options outstanding.
Our headcount is 44 employees, up from 26 at the start of the quarter.
Our stock price is up 725% as of this past Friday, since our January 2, 2018 close. Since Thursday of last week IVST saw more than double average trading volume, following the StemVax announcement.
We received notice that Winslow Asset Management registered as a shareholder, marking our first institutional shareholder position.
We closed several key contracts with organizations ranging from local governments, to the United States Navy, University Hospitals, Cleveland Indians, University of Louisiana, Iowa Department of Transportation, Houston Metro, Tarkette and a $650K exclusive contact from Byram Healthcare, a division of a Fortune 500 Company.
We’ve got a world-class team including two independent members of our Board of Directors, and our key corporate leadership is highlighted on our new corporate website.
https://finance.yahoo.com/news/innovest-globa...00125.html
(0)
(0)